BCL2L1 and cancer: For example, the BCL-XL-specific PROTAC DT2216 from the Zhou and Zheng groups can lead to BCL-XL degradation in cancer cells but not in platelets due to the low expression of the von Hippel-Lindau (VHL) E3 ligase in platelets [44, 63, 64].